OBJECTIVES The aim of this study was to investigate N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels and recent heart failure (HF) hospitalization as predictors of future events in heart failure -preserved ejection fraction (HF-PEF).
Failure with Preserved systolic function) trial (6) .
METHODS
I-PRESERVE examined the effects of the angiotensin II receptor antagonist irbesartan on morbidity and mortality in patients with HF-PEF; outcomes of patients randomly assigned to receive irbesartan did not differ from those of patient who received placebo (6) .
In the present study, we analyzed clinical outcomes of HF hospitalization and CV death according to baseline NT-proBNP concentration, history of recent hospitalization for HF, and combinations of those factors.
PATIENTS. The rationale, design, and results from I-PRESERVE have been described previously in detail (7) (8) (9) . The trial enrolled 4,028 patients with left ventricular ejection fraction of at least 45% who were $60 years of age and had HF symptoms corresponding to New York Heart Association (NYHA) functional classes II to IV. Patients in NYHA functional class II were required to have had a hospitalization for HF within 6 months before enrollment.
Although most patients enrolled in I-PRESERVE had their concentration of NT-proBNP measured at their randomization visit, the result was not available to investigators at the time of enrolment, unlike TOPCAT, and this measurement was not used to determine study eligibility (9) .
We restricted our main analysis to patients who were in NYHA functional class III or IV at baseline and who had had NT-proBNP concentration measured ( Figure 1) . We excluded patients in NYHA functional class II from the main analysis because they were all required to have a recent HF hospitalization. However, in a sensitivity analysis, we carried out the same analyses in all patients with a NT-proBNP measurement, regardless of NYHA functional class.
We report baseline characteristics of patients according to the presence or absence of HF hospitalization in the 6 months prior to study inclusion and baseline level of NT-proBNP, dichotomized at 360 pg/ml (the entry threshold for TOPCAT). In the sensitivity analysis, we dichotomized NT-proBNP at 300 pg/ml.
OUTCOMES. We studied the composite outcome of CV death or HF hospitalization, as well as each of the components of this composite separately. Deaths and hospitalizations were adjudicated by an independent endpoint committee.
STATISTICAL ANALYSES. Baseline characteristics are mean AE SD for continuous variables and frequencies and percentages for categorical variables. Differences in baseline characteristics according to recent hospitalization for HF and NT-proBNP levels were assessed using a chi-square test for categorical covariates and we assessed risk estimates in a multivariate analysis previously validated for the I-PRESERVE study (8) , which included adjustments for age, sex, body mass index, ejection fraction, heart rate, systolic blood pressure, ischemic cause, congestion on radiographs, kidney function, blood urea nitrogen level, and neutrophil count and history of atrial fibrillation, myocardial infarction, diabetes, and stroke/transient ischemic attack.
Analyses were repeated using the 4 specific combinations of the 2 risk predictors as a categorical variable: 1) no recent hospitalization for HF plus NTproBNP #360 pg/ml (reference); 2) no recent hospitalization for HF plus NT-proBNP>360 pg/ml; 3) recent hospitalization for HF plus NT-proBNP #360 pg/ml; and 4) recent hospitalization for HF plus NT-proBNP >360 pg/ml. In a sensitivity analysis including NYHA II patients, the same groups were created using an NT-proBNP cutpoint of 300 pg/ml.
We also performed a subgroup analysis of patients with atrial fibrillation to assess whether the prognostic value of elevated NT-proBNP (>360 pg/ml) was similar or different in these patients.
We did not include randomized treatment in our model because irbesartan had no effect on any outcome in I-PRESERVE. All p values are 2-sided, and a p value of <0.05 was considered significant. All analyses were performed separately for each dataset, using Stata version 11 software (Stata Corp., College Station, Texas).
RESULTS
Characteristics of the patients analyzed are listed in Table 1 
PATIENTS WITH AN ELEVATED NT-proBNP LEVEL
COMPARED TO THOSE WITHOUT. Baseline NTproBNP was >360 pg/ml in 1,299 patients (47%). Patients with an elevated NT-proBNP level were older (mean age 73 vs. 70 years of age), more likely to be male (44% vs. 34%, respectively), and had markedly lower mean eGFR (63 vs. 74 l/min/1.73m 2 , respectively). They were also more likely to have ischemic heart disease (31% vs. 22%, respectively) and had a 4-fold higher prevalence of AF (44% vs. 10%, respectively) compared to patients with NT-proBNP #360 pg/ml. All other comorbidities were also more common in patients with higher NT-proBNP levels, and use of all medications listed was more frequent in these patients, with the exception of calcium channel blockers.
Rates of the composite endpoint of HF hospitalization and CV death are presented in Table 2 and Figure 2 . This composite outcome occurred in 674 patients (24%) overall, with a rate per 100 patient years of 6.56 (95% CI: 6.08 to 7.07).
OUTCOMES ACCORDING TO HISTORY OF HF
HOSPITALIZATION. In a sex-and age-adjusted Cox regression model, patients with recent HF hospitalization were more than twice as likely to Likelihood ratio tests ( of those with NT-proBNP >360 pg/ml also had had a recent HF hospitalization. We combined the 2 risk predictors to create 4 distinct risk groups ( Table 2) .
Event rates for the composite endpoint and HF hospitalization and CV death separately are shown in Table 2 . NT-proBNP level >360 pg/ml was associated with a higher risk of CV death than a recent HF hospitalization in the previous 6 months (HR: 1.63; 95% CI:
1.10 to 2.42; p < 0.01). We found no significant differences for the risk of HF hospitalization and the composite outcome, although each risk predictor alone or combined was more strongly associated with the risk of HF hospitalization than CV death.
Finally, combining the 2 risk predictors yielded improved risk prediction compared to each of the separate, and more so for the risk of HF hospitalization ( Table 3) . with atrial fibrillation (and small number of events in these patients), no definitive conclusion can be drawn, and it remains possible that a higher NTproBNP threshold would be more appropriate for risk prediction in these patients than in patients without atrial fibrillation. In the present study, the rate of CV death or HF hospitalization in patients with an elevated NT-proBNP was 11.5 per 100 personyears. However, in TOPCAT, it is likely that NTproBNP was used primarily to determine eligibility in patients without a recent HF hospitalization (4). In I-PRESERVE, the rate of CV death or HF hospitalization in patients with elevated NT-proBNP but without a recent HF hospitalization was only 8.2 per 100 STUDY LIMITATIONS. As with any study of this type, there are some limitations. I-PRESERVE had specific inclusion and exclusion criteria, therefore our findings may not be generalized to all patients with HF-PEF. This was also not a pre-specified analysis. Our main analysis excluded patients in NYHA functional class II because the protocol required such patients to have a recent history of heart failure hospitalization, although the sensitivity analysis including all patients gave similar findings.
In the present study, we focused on the identification of HF-PEF patients at high risk for HF hospitalization and CV death. However, it is important to remember that these are not the only important outcomes in heart failure and improvement in symptoms and quality of life are key goals of therapy in HF-PEF. Kingdom. E-mail: john.mcmurray@glasgow.ac.uk. 
